Chong Chyn Chua - Concepedia

Author

Chong Chyn Chua

Also Known As

C. C. Chua, C. Chua, C. Chyn Chua, C.C. Chua, Chen En Lucas Chua, Chong C Chua, Chong C. Chua, Chong Chyn Chua, Chyn C. Chua, Chyn Chua

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Monash University The University of Melbourne The Alfred Hospital The Royal Melbourne Hospital Peter MacCallum Cancer Centre

About

Chong Chyn Chua is an author at Monash University specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	354
2	Immunology	5	5	332
3	Health Sciences	4	4	318
4	Cell Biology	2	2	113
5	Pathology	1	1	19

Chong Chyn Chua

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri, Blood	2020	628
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy Chong Chyn Chua, Andrew W. Roberts, John Reynolds, Journal of Clinical Oncology ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2020	183
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, Blood Hematological MalignancyBax Confer ResistanceMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2022	95
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Uma Borate, Jordi Esteve, Kimmo Porkka, Blood	2019	85
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia Chong Chyn Chua, Danielle Hammond, Andrew Kent, Blood Advances	2022	58
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) Ing Soo Tiong, Devendra Hiwase, Emad Abro, Journal of Clinical Oncology	2024	24
Retrospective review on isolated distal deep vein thrombosis (IDDVT) — A benign entity or not? Prahlad Ho, Hui Yin Lim, Chong Chyn Chua, Thrombosis Research ThrombosisVenous DiseaseVenous ThrombosisCardiovascular DiseaseVenous Disease Treatment	2016	22
Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia Donia M. Moujalled, Fiona C. Brown, Giovanna Pomilio, Blood	2020	20
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells Charis E. Teh, Hongke Peng, Meng-Xiao Luo, Blood Advances ImmunologyNk CellsPathologyImmunotherapyHematological Malignancy	2022	19
Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma Chong Chyn Chua, Hui Yin Lim, Khai Li Chai, Bone Marrow Transplantation Hematological MalignancyHealth SciencesMedicineStem Cell MobilizationStem Cells	2018	18

Page 1